Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986278 Batched method, Dose A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1, Sequence 1 | EXPERIMENTAL | - |
| Part 1, Sequence 2 | EXPERIMENTAL | - |
| Part 2, Sequence 1 | EXPERIMENTAL | - |
| Part 2, Sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986278 Batched method, Dose A | DRUG | Specified dose on specified days |
| BMS-986278 Batched method, Dose B | DRUG | Specified dose on specified days |
| BMS-986278 Continuous method | DRUG | Specified dose on specified days |
Inclusion Criteria: * Healthy female individuals not of childbearing potential (INOCBP) and males, healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory assessment results as determined by the investigator. * Body mass ...
BMS-986278 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its comparative bioavailability in healthy participants. The drug is not approved for any indication and remains in clinical testing.
BMS-986278 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's properties in healthy volunteers.
BMS-986278 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation.
BMS-986278 has one completed Phase 1 clinical trial, NCT06715683, titled 'A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants.' The trial enrolled 48 participants in the United States and was a controlled, randomized study.
BMS-986278 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial in healthy volunteers is part of early-stage research, and the drug has not yet received marketing approval.